Medical Oncologist
EGFR Exon 20 Insertion
EGFR Exon 20 Insertion: — Why It Is Different and Harder to Treat
EGFR exon 20 insertion is a subtype of EGFR mutation in lung cancer that does not respond to the drugs used for common EGFR mutations. Bispecific antibodies and exon-20-specific tyrosine kinase inhibitors are now available for this subtype. The first step to reaching them is knowing your exact mutation, which requires comprehensive genomic testing — not a standard EGFR test.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
- Not the common EGFR mutation — Exon 20 insertion is a distinct subtype that behaves differently from the two common EGFR mutations, and it needs different drugs.
- Often missed by standard testing — Standard PCR-based EGFR tests are designed for the common mutations and frequently miss exon 20 insertions. Next-generation sequencing is needed.
- Specific drugs now exist — Bispecific antibodies and exon-20-specific tyrosine kinase inhibitors have been developed specifically for this mutation and are approved or in trials.
- Early identification changes options — Knowing your specific mutation before starting treatment helps your oncologist reach the right drug, or a clinical trial, rather than treating without the information.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
EGFR exon 20 insertion is a subtype of EGFR mutation in lung cancer that does not respond to most standard EGFR-targeted drugs. Drugs designed specifically for it — bispecific antibodies and exon-20-specific tyrosine kinase inhibitors — are now available. NCCN recommends comprehensive genomic testing to identify it, because standard EGFR tests often miss this subtype entirely.
Why does exon 20 insertion not respond to standard EGFR drugs?
Common EGFR drugs — including erlotinib, gefitinib, afatinib and osimertinib — work by fitting into the active site of the EGFR protein and blocking its growth signal. The two most common EGFR mutations change that site in a way those drugs exploit.
Exon 20 insertions change a different part of the protein — the C-helix region near the active site — in a way that physically blocks those same drugs from entering. The structural problem is different, so the drugs designed for common mutations provide very little benefit here.
NCCN and ESMO both classify exon 20 insertion as a distinct molecular subtype that requires its own treatment approach, separate from other EGFR-mutant lung cancers. This is why your specific mutation subtype matters, not just the gene name.
How do you reach the right diagnosis and treatment?
Biopsy
Tissue from your tumour is taken — from the lung, a lymph node, or a site where the cancer has spread — and sent to the pathology laboratory. The sample is stored and can usually be used for further testing without a repeat biopsy.
Request next-generation sequencing
Ask your oncologist to order comprehensive genomic profiling (NGS) on your sample. This tests for hundreds of mutations at once, including all exon 20 insertions. A standard EGFR PCR test will often miss this mutation entirely and should not be relied on alone.
Confirm the exact variant
Exon 20 insertions are not all identical — the location of the insertion within exon 20 varies. Your report will name the specific variant. This detail matters because some variants respond differently to individual drugs.
Review available treatment options
Your oncologist matches your specific mutation to available drugs and open clinical trials. If amivantamab or another approved agent is accessible and appropriate for your stage, that becomes the first targeted treatment conversation.
Begin treatment as day care
Treatments approved for exon 20 insertion are given as day-care intravenous infusions or oral tablets, depending on the drug. Most patients do not need overnight admission.
What treatment options are available for exon 20 insertion?
Two drug classes have been developed specifically for EGFR exon 20 insertion. The first is bispecific antibodies — proteins engineered to block two receptors at once. The second is a newer generation of tyrosine kinase inhibitors designed to fit the altered EGFR protein structure, unlike the older TKIs that cannot.
Amivantamab, a bispecific antibody targeting both EGFR and MET, has received FDA approval for non-small cell lung cancer with exon 20 insertion after progression on platinum-based chemotherapy. NCCN lists it as a preferred option in that setting.
For many patients in India, platinum-based chemotherapy remains the starting point while access to exon-20-specific agents is being established. Ask your oncologist whether amivantamab or another approved agent is accessible at your centre, or whether a clinical trial is open to you.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer from a specialist
45 minutes, your reports reviewed, your questions answered in plain language.
What does treatment involve once it starts?
Amivantamab is given as an intravenous infusion. The first infusion is often divided across two consecutive days to reduce the risk of an infusion-related reaction; later doses are given in a single session.
Side effects from this drug class include skin changes, nail changes and swelling — particularly in the legs — because EGFR signalling also plays a role in normal skin cells. Your team will tell you what to expect and which changes to report rather than manage at home.
Response is assessed by repeat imaging after a set number of treatment cycles. Your oncologist will explain the scan schedule and what the results are measuring.
Drugs used in EGFR exon 20 insertion — what each one is
- Amivantamab
- A bispecific antibody given by intravenous infusion. It targets both EGFR and MET proteins on cancer cell surfaces simultaneously. FDA-approved for non-small cell lung cancer with exon 20 insertion after platinum-based chemotherapy. NCCN lists it as a preferred option in this setting. Availability in India varies by centre — ask your oncologist directly.
- Exon-20-specific tyrosine kinase inhibitors
- A newer class of oral tablets designed to fit the altered EGFR protein structure caused by exon 20 insertions — unlike older TKIs, which cannot. Several are under investigation or have received regulatory approval in specific countries. Your oncologist can advise which, if any, are accessible at your treating centre or through a clinical trial.
- Standard EGFR tyrosine kinase inhibitors (erlotinib, gefitinib, osimertinib)
- These are not appropriate for exon 20 insertion. They are designed for the common EGFR mutations and have very limited activity against this subtype. NCCN and ESMO guidance does not list them as treatment options for exon 20 insertion. Receiving them would mean side effects without meaningful benefit.
- Platinum-based chemotherapy
- Regimens using carboplatin or cisplatin, usually combined with another drug. For many patients with exon 20 insertion, this remains a standard option — particularly when specific targeted agents are not yet accessible. It can also be combined with amivantamab in some approved protocols.
Did you know?
Standard EGFR tests used in many hospitals are designed to detect the two most common mutations — exon 19 deletion and L858R. They can miss EGFR exon 20 insertion entirely, leaving patients without knowledge that a targeted option may exist for them.
NCCN guidelines recommend broad molecular profiling — next-generation sequencing — for all patients with non-squamous non-small cell lung cancer at the time of diagnosis, specifically to close this testing gap.
Source: NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer
Explore 119 more Targeted Therapy Basics, Testing & Your Cancer Type topics
Mutation & Target-Specific Pages
- ALK-Positive Lung Cancer: Drugs, Response and What Comes Next
- Antiangiogenic Drugs (VEGF Inhibitors): How Starving a Tumour Works
- BCR-ABL and the Philadelphia Chromosome in CML
- BRAF V600E Mutation: Targeted Therapy Across Multiple Cancers
- BRCA vs HRD Testing: Which One Determines PARP Inhibitor Eligibility?
- BRCA1 and BRCA2 Mutations in Cancer Treatment: PARP Inhibitors
- BTK Inhibitors in CLL and Lymphoma
- CD20, CD38 and Other Antibody Targets in Blood Cancers
- CDK4/6 Inhibitors in Hormone-Positive Breast Cancer
- Co-Mutations: When You Have Two Mutations at Once
- EGFR Exon 20 Insertion: Why It's Different and Harder to Treat
- EGFR Mutation in Lung Cancer: Complete Patient Guide
- ESR1 Mutation: Why Your Hormone Therapy Stopped Working
- FGFR Alterations in Bladder and Bile Duct Cancer
- FLT3 Mutation in AML: What It Means for Your Prognosis
- HER2 Mutation in Lung and Gastric Cancer
- HER2-Low Breast Cancer: A New Category That Changes Treatment
- HER2-Positive Breast Cancer: The Full Targeted Therapy Roadmap
- IDH1 and IDH2 Mutations in Glioma, AML and Bile Duct Cancer
- KIT and PDGFRA Mutations in GIST
- KRAS G12C Mutation: The Target That Was Undruggable for 40 Years
- KRAS Mutation but Not G12C: What Are My Options?
- MET Exon 14 Skipping and MET Amplification Explained
- MSI-High and Mismatch Repair Deficiency: Testing and Treatment
- NRG1, MET, RET and Other Rare Fusions: Where to Get Tested
- NTRK Fusion: One Drug for Many Different Cancers
- Osimertinib: What to Expect, Side Effects and How Long It Works
- PALB2, ATM and Other BRCA-Like Genes: Do They Get the Same Drugs?
- PIK3CA Mutation in Breast Cancer: Alpelisib and What to Expect
- PSMA and AR-Targeted Therapy in Prostate Cancer
- RET Fusion Cancer: Lung, Thyroid and Beyond
- ROS1-Positive Cancer: A Rare Mutation with Excellent Options
- TP53 Mutation: Why There's Still No Targeted Drug for It
- Understanding Variant Allele Frequency (VAF) in Your Report
- What If My Mutation Has No Approved Drug Yet?
- mTOR Inhibitors in Cancer: Everolimus and Temsirolimus
Before You Start - Preparation & Baseline
- 25 Questions to Ask Your Oncologist Before Starting Targeted Therapy
- Before You Start Targeted Therapy: The Complete Preparation Checklist
- Dental Check-Up Before Cancer Treatment: Why It Matters
- Financial Planning Before Starting Long-Term Targeted Therapy
- How Long After Surgery Can You Start Targeted Therapy?
- How to Store Your Targeted Therapy Tablets Correctly
- Setting Up a Dosing Routine You Won't Forget
- Should Targeted Therapy Be Taken With Food or on an Empty Stomach?
- Vaccinations Before and During Cancer Treatment
- What to Expect in Your First Month on Targeted Therapy
- Which Baseline Tests Are Done Before Starting a TKI?
- Which of Your Existing Medicines Must Stop Before Targeted Therapy
- Why You Need an ECHO and ECG Before Certain Cancer Drugs
Biomarker & Molecular Testing
- Can Mutation Testing Be Done on an Old Biopsy Block or Slides?
- Cost of NGS and Mutation Testing in India: 2026 Price Guide
- Do I Need Genetic Testing Before Starting Targeted Therapy?
- Germline vs Somatic Testing: The Difference Nobody Explains Properly
- Getting a Second Opinion on Your Genomic Report
- How Long Do Mutation Test Results Take in India? Realistic Timelines
- How to Read Your Molecular Pathology Report, Line by Line
- IHC, FISH, PCR or NGS: Which Mutation Test Is Right for Your Cancer?
- Is Mutation Testing Worth It If I Can't Afford the Drug?
- Liquid Biopsy vs Tissue Biopsy: Which Test Do You Need?
- My Report Says a Mutation Is 'Actionable': What Does That Mean?
- No Mutation Found in My Report: What Are My Options Now?
- Should I Start Chemotherapy While Waiting for Mutation Results?
- Should You Repeat Molecular Testing After Your Cancer Progresses?
- Single-Gene Test or Full Panel? How to Choose Without Wasting Money
- What Are PD-L1, TMB and MSI, and Do They Affect Targeted Therapy?
- What Does 'Variant of Uncertain Significance' (VUS) Mean?
- What Happens If There Isn't Enough Tissue for Mutation Testing?
- What Is NGS (Next-Generation Sequencing) Testing in Cancer?
- What Is a Molecular Tumour Board and Why Should You Want One?
- Which Cancers Should Always Be Tested for Mutations? A Checklist
- ctDNA and MRD Testing: Tracking Cancer Through a Blood Test
Cancer-Type Specific Targeted Therapy
- CML Treatment with TKIs: Living a Normal Life Span
- Cancer of Unknown Primary: Can Molecular Testing Help?
- GIST Treatment: Why This Cancer Changed Targeted Therapy Forever
- Targeted Therapy for Bile Duct Cancer (Cholangiocarcinoma)
- Targeted Therapy for Bladder and Urothelial Cancer
- Targeted Therapy for Brain Tumours and Glioma
- Targeted Therapy for Breast Cancer: HER2, HR+ and Triple Negative
- Targeted Therapy for CLL and Lymphoma
- Targeted Therapy for Cervical and Endometrial Cancer
- Targeted Therapy for Childhood Cancers
- Targeted Therapy for Colorectal Cancer: RAS, BRAF and HER2
- Targeted Therapy for Head and Neck Cancer
- Targeted Therapy for Kidney Cancer (RCC)
- Targeted Therapy for Liver Cancer (HCC)
- Targeted Therapy for Lung Cancer: Every Mutation and Drug Explained
- Targeted Therapy for Melanoma: BRAF and MEK Inhibitors
- Targeted Therapy for Multiple Myeloma
- Targeted Therapy for Neuroendocrine Tumours
- Targeted Therapy for Ovarian Cancer: PARP Inhibitors and Beyond
- Targeted Therapy for Pancreatic Cancer: Limited but Real Options
- Targeted Therapy for Prostate Cancer
- Targeted Therapy for Sarcoma
- Targeted Therapy for Stomach and Gastroesophageal Cancer
- Targeted Therapy for Thyroid Cancer
- Targeted Therapy in AML: Beyond Standard Chemotherapy
- Tumour-Agnostic Drugs: When the Mutation Matters More Than the Organ
Foundations & How Targeted Therapy Works
- Adjuvant and Neoadjuvant Targeted Therapy: Treatment Before or After Surgery
- Antibody-Drug Conjugates (ADCs): The Smart Bombs of Cancer Treatment
- Biosimilars and Generic Targeted Therapy Drugs: What They Are
- Can Targeted Therapy Be Combined with Chemotherapy or Radiation?
- Can Targeted Therapy Cure Cancer? An Honest Answer
- First-Line, Second-Line and Beyond: How Treatment Lines Work
- How Doctors Decide Between Chemo, Immunotherapy and Targeted Therapy
- How Does Targeted Therapy Actually Work? Explained Without Jargon
- How Long Does Targeted Therapy Take to Start Working?
- Is Targeted Therapy Painful? What the Treatment Actually Feels Like
- Is Targeted Therapy a Type of Chemotherapy? Clearing Up the Confusion
- Oral Tablets vs IV Infusion Targeted Therapy: What's the Difference?
- Precision Oncology vs Personalised Medicine: Are They the Same Thing?
- Targeted Therapy Success Rates: What the Numbers Really Mean
- Targeted Therapy for Stage 4 Cancer: What You Can Realistically Expect
- Targeted Therapy vs Chemotherapy: 12 Differences That Actually Matter
- Targeted Therapy vs Immunotherapy: Which One Is Right for You?
- The 8 Main Types of Targeted Therapy Drugs (With Examples)
- What Do Cancer Drug Endings Like -nib, -mab and -tinib Mean?
- What Is Targeted Therapy for Cancer? A Complete Patient Guide
- Which Cancers Can Be Treated with Targeted Therapy? Full List
- Why Didn't My Doctor Recommend Targeted Therapy for Me?
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Is EGFR exon 20 insertion the same as being EGFR positive?
No, and this distinction determines your treatment. When oncologists say 'EGFR positive,' they usually mean the two common mutations — exon 19 deletion or L858R. Exon 20 insertion sits within the same gene but behaves differently and does not respond to the drugs used for those common mutations. Your report needs to name the specific subtype, not just the gene, before treatment decisions can be made. If your report says only 'EGFR positive' without naming the mutation, ask what exactly was detected.
Can I take osimertinib (Tagrisso) for exon 20 insertion?
No. Osimertinib is highly effective for the common EGFR mutations — exon 19 deletion, L858R and the T790M resistance mutation — but has very limited activity against exon 20 insertions. NCCN and ESMO do not list it as a treatment option for this subtype. Receiving it would mean its side effects without the benefit it provides in other settings. If you have been told osimertinib is appropriate, ask your oncologist to confirm your specific mutation subtype in writing before starting.
How do I know if my EGFR test detected or missed this mutation?
Ask your oncologist what type of test was performed and request the full report. If the test was a rapid PCR panel — which covers only a small number of known variants — exon 20 insertion may not have been tested for at all. If the report shows next-generation sequencing or comprehensive genomic profiling and came back negative, you can have more confidence. Ask directly: was exon 20 insertion specifically included in the testing? If you are unsure, requesting repeat testing on your stored tissue sample is a reasonable question to raise.
Is amivantamab available in India?
Amivantamab has been approved in several countries and is available at certain oncology centres in India through approved supply channels. Access and cost vary considerably by centre and city. Ask your oncologist whether it is obtainable at your treating centre, whether a referral to a larger cancer centre is appropriate, and whether any patient assistance programmes apply. Availability changes over time, so this is worth asking directly at each appointment rather than assuming the answer is fixed.
What are the options if no targeted drug is accessible to me?
Platinum-based chemotherapy is an active and established treatment for non-small cell lung cancer and remains appropriate for many patients with exon 20 insertion. Your oncologist will advise whether adding an immunotherapy agent is appropriate for your tumour's PD-L1 level and your general fitness. It is also worth asking about clinical trials — several studies of new exon-20-specific agents recruit patients at centres in India. Ask your oncologist to check the Clinical Trials Registry of India at ctri.nic.in for open studies relevant to your mutation.
Will immunotherapy work for exon 20 insertion?
Response to immunotherapy is determined mainly by PD-L1 expression levels and tumour mutational burden — not by the EGFR mutation subtype itself. Some patients with exon 20 insertion have tumours that express enough PD-L1 for immunotherapy to be considered alongside other treatment; others do not. Your oncologist will assess these markers separately from the mutation report and explain whether immunotherapy is part of the plan. We do not yet have enough data to predict individual responses in this subtype with confidence, and NCCN and ESMO guidance in this area continues to evolve.